Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Shareholder Meeting (May 2024)
40 slides from Fresenius SE & Co. KGaA's shareholder meeting presentation, May 17, 2024
Slide 1: Fresenius Annual General Meeting
Fresenius Annual General Meeting Frankfurt am Main, May 17, 2024 Presentation of Michael Sen, CEO of the Management Board 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 2: Fresenius
= Fresenius
Slide 3: 17.05.2024 | Fresenius Annual General Meeting 2024
17.05.2024 | Fresenius Annual General Meeting 2024
Slide 4: Every fourth blood bag worldwide comes from Fresenius
Every fourth blood bag worldwide comes from Fresenius 27 million blood bags sold in 2023 17.05.2024 | Fresenius Annual General Meeting 2024 4
Slide 5: #FutureFresenius
#FutureFresenius 17.05.2024 | Fresenius Annual General Meeting 2024 5
Slide 6: Four phases to becoming the leading healthcare company
#FutureFresenius Four phases to becoming the leading healthcare company REIMAGINE REJUVENATE REVITALIZE RESET 17.05.2024 | Fresenius Annual General Meeting 2024 6
Slide 7: Four phases to becoming the leading healthcare company
#FutureFresenius Four phases to becoming the leading healthcare company REIMAGINE REJUVENATE REVITALIZE RESET 17.05.2024 | Fresenius Annual General Meeting 2024 7
Slide 8: Share price: continuous improvement since turnaround
Share price: continuous improvement since turnaround 17.05.2024 | Fresenius Annual General Meeting 2024 8
Slide 9: Raised outlook for 2024 fiscal year
Raised outlook for 2024 fiscal year 4-7% 6 - 10 % Organic EBIT growth revenue growth before special items in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 9
Slide 10: 17.05.2024 | Fresenius Annual General Meeting 2024
17.05.2024 | Fresenius Annual General Meeting 2024 10
Slide 11: Historic step through deconsolidation
Historic step through deconsolidation For greater freedom and responsibility 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 12: Simplified structure, sharper focus
Simplified structure, sharper focus 32 % stake Fresenius Kabi Fresenius Helios Pharma Biopharma Nutrition MedTech 17.05.2024 | Fresenius Annual General Meeting 2024 12
Slide 13: 2023 fiscal year a success
2023 fiscal year a success Revenue €22.3bn +6 %* EBIT €2.3bn +2 %** EBIT margin 10.1 % Operating cash flow €2.1bn +5 % * Organic growth ** EBIT growth rate in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 13
Slide 14: Consistently good performance Fresenius Kabi and Fresenius Helios
Consistently good performance Fresenius Kabi and Fresenius Helios Q1 23 Q2 23 Q3 23 FY 23 Revenue* +7 %** +7 %** +7 %** +7 %** Fresenius Kabi EBIT -4 % +1 % +2 % +3 % Revenue* +5 % +6 % +6 % +5 % Fresenius Helios EBIT +2 % +3 % +4 % +4 % Before special items; EBIT growth rates in constant currency *
Slide 15: Growth on a broad basis: 2023 at Fresenius Kabi
Growth on a broad basis 2023 fiscal year at Fresenius Kabi Fresenius Kabi Revenue* €8bn +7 %** Ambition level: 4 - 7 % EBIT €1.15bn +3 %*** 14.3 % Ambition level: 14 - 17 % EBIT margin * Organic growth ** Excluding the significant inflationary effects in Argentina *** EBIT growth rates in constant c
Slide 16: Digitalization paying off: 2023 at Fresenius Helios
Digitalization paying off 2023 fiscal year at Fresenius Helios Fresenius Helios Revenue* €12.3bn +5 % Ambition level: 3 - 5 % EBIT €1.2bn +4 %** 10.0 % Ambition level: 9 - 11 % EBIT margin * Organic growth ** EBIT growth rates in constant currency 17.05.2024 | Fresenius Annual General Meeting 2024 1
Slide 17: On track to achieve ambitious savings targets
On track to achieve ambitious savings targets Cost and efficiency program leading to greater competitiveness ~ €400 ~ €350 million ~ €280 million ~ €200 million million Old New Expected Actuals target target 2023 2025 17.05.2024 | Fresenius Annual General Meeting 2024 17
Slide 18: Fresenius Kabi
Fresenius Kabi 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 19: Fresenius Kabi
Fresenius Kabi Innovative development and production platform. Strong network for biopharmaceuticals. 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 20: Fresenius Kabi Biopharma
Fresenius Kabi Biopharma Cost-efficient and highly effective alternatives for treating cancer and autoimmune diseases. Excellent start with biosimilar Tyenne® in USA and EU. 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 21: Fresenius Helios
Fresenius Helios 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 22: Fresenius Helios
Fresenius Helios Modern technologies in daily clinical practice for optimized patient care. 20 DaVinci surgical robots in use at Helios hospitals in Germany. 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 23: Fresenius Helios
Fresenius Helios Casiopea digital healthcare platform simplifies clinical processes. 6 million active users in Spain (approx. 12.5% of population). 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 24: 17.05.2024 | Fresenius Annual General Meeting 2024
17.05.2024 | Fresenius Annual General Meeting 2024 24
Slide 25: Robust and dynamic growth: global healthcare services market
Robust and dynamic growth The global market for healthcare services ~ $8 ~ $10 trillion trillion market volume market volume in 2027 in 2023 Source: Projections for the International Healthcare Sector, 2023 (The Business Research Company) 17.05.2024 | Fresenius Annual General Meeting 2024 25
Slide 26: Driver of the healthcare industry: technology
Driver of the healthcare industry: technology 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 27: Artificial intelligence in healthcare
Artificial intelligence in healthcare Market size in US dollars ~ $188 billion $200 billion $150 billion $100 billion ~ $21 billion $50 billion 2023 2030 Source: Artificial Intelligence (AI) in Healthcare Market Size Worldwide from 2021 to 2030 (Statista) 17.05.2024 | Fresenius Annual General Meetin
Slide 28: Driver of the healthcare industry: data
Driver of the healthcare industry: data 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 29: Digitalization of healthcare
Digitalization of healthcare “Digitizing the patient healthcare journey offers a wide range of benefits and solutions to healthcare system challenges by enhancing efficiency, improving patient outcomes, 97% and increasing access to healthcare.” of health data World Economic Forum, Transforming Healt
Slide 30: Driver of the healthcare industry: biomedical research
Driver of the healthcare industry: biomedical research 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 31: Focus on people
Focus on people 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 32: 3 platforms for profitable growth
3 platforms for profitable growth (Bio)Pharma MedTech Care Provision 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 33: Market potential of the platforms: €1 trillion
Market potential of the 3 platforms €1 trillion 17.05.2024 | Fresenius Annual General Meeting 2024 33
Slide 34: The Fresenius ecosystem: a strong global network
The Fresenius ecosystem A strong global network 17.05.2024 | Fresenius Annual General Meeting 2024 34
Slide 35: Team Fresenius is growing
Team Fresenius is growing +5,000 employees in 2023 6,700 apprentices and dual students 40 apprenticeships 30 dual study programs 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 36: ESG influences our actions
ESG influences our actions On course for climate neutrality Climate -50 % neutral CO2 emissions -22 % since 2020 CO2 emissions since 2020 2020 2023 2030 2040 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 37: A leading global company
A leading global company 80 countries 190,000+ colleagues 150 nationalities 17.05.2024 | Fresenius Annual General Meeting 2024 37
Slide 38: Active for our patients worldwide
Active for our patients worldwide 26 million patients 450 million lives touched 17.05.2024 | Fresenius Annual General Meeting 2024
Slide 39: 17.05.2024 | Fresenius Annual General Meeting 2024
17.05.2024 | Fresenius Annual General Meeting 2024 39
Slide 40: Committed to Life
COMMITTED TO LIFE 17.05.2024 | Fresenius Annual General Meeting 2024 40
Fresenius SE & Co. KGaA — Shareholder Meeting (May 2024) on 6ix